Comparison of Serum Anti-Mullerian Hormone Levels Following Uterine Artery Ligation for PPH.
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 88
- Locations
- 1
- Primary Endpoint
- 1- Anti-Mullerian Hormone levels variation
Study Overview
Brief Summary
Anti-Mullerian hormone (AMH) is a marker for ovarian reserve. There are many studies about AMH changes in ovarian surgery, but little is known for other surgeries. We seek to investigate the hormone variations before and after uterine artey ligation for postpartum hemorrage (PPH)
Detailed Description
All patients belong to the same group. The blood samples will be collected at the time of surgery and 3 months after surgery from the patients who need uterine artery ligation for PPH. The blood samples will be centrifuged within 2 hours after being obtained and assessed on the same day. AMH concentrations will be measured with an enzymatically amplified two-sided immunoassay
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to 40 Years (Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •age 18- 40 years
- •no systemic or endocrine diseases
- •patients who had uterine artery ligation due to PPH
Exclusion Criteria
- •Pregnancy with IVF or oosit donation
- •Patients with endocrinopathy, diseases which require radiotherapy and chemotherapy etc.
- •Patients with BMI >40
Outcomes
Primary Outcomes
1- Anti-Mullerian Hormone levels variation
Time Frame: 3 months
Anti-Mullerian Hormone levels before and 3 months after surgery
Secondary Outcomes
No secondary outcomes reported
Investigators
Pınar Yalcin bahat
Principal Investigator
Kanuni Sultan Suleyman Training and Research Hospital